These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 12825097)
41. Global experiences with vardenafil in men with erectile dysfunction and underlying conditions. Eardley I; Lee JC; Guay AT Int J Clin Pract; 2008 Oct; 62(10):1594-603. PubMed ID: 18822030 [TBL] [Abstract][Full Text] [Related]
42. A comparative review of apomorphine formulations for erectile dysfunction : recommendations for use in the elderly. Briganti A; Chun FK; Salonia A; Zanni G; Dehò F; Barbieri L; Karakiewicz PI; Rigatti P; Montorsi F Drugs Aging; 2006; 23(4):309-19. PubMed ID: 16732690 [TBL] [Abstract][Full Text] [Related]
43. The evaluation of apomorphine for the treatment of erectile dysfunction. Mohee A; Bretsztajn L; Eardley I Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1447-53. PubMed ID: 22998347 [TBL] [Abstract][Full Text] [Related]
44. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Carson C; Shabsigh R; Segal S; Murphy A; Fredlund P; Kuepfer C; Urology; 2005 Feb; 65(2):353-9. PubMed ID: 15708052 [TBL] [Abstract][Full Text] [Related]
45. Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction--an open, randomized cross-over study with flexible dosing. Porst H; Behre HM; Jungwirth A; Burkart M Eur J Med Res; 2007 Feb; 12(2):61-7. PubMed ID: 17369119 [TBL] [Abstract][Full Text] [Related]
46. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction. Axilrod AC Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309 [TBL] [Abstract][Full Text] [Related]
47. Apomorphine (Apokyn) for advanced Parkinson's Disease. Med Lett Drugs Ther; 2005 Jan; 47(1200):7-8. PubMed ID: 15647705 [TBL] [Abstract][Full Text] [Related]
48. Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. Reffelmann T; Kloner RA Expert Opin Drug Saf; 2005 May; 4(3):531-40. PubMed ID: 15934858 [TBL] [Abstract][Full Text] [Related]
49. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. Chen JJ; Obering C Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444 [TBL] [Abstract][Full Text] [Related]
50. Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra). Montorsi F; Padma-Nathan H; Glina S Urology; 2006 Sep; 68(3 Suppl):26-37. PubMed ID: 17011373 [TBL] [Abstract][Full Text] [Related]
51. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. Hellstrom WJ Int J Clin Pract; 2007 Sep; 61(9):1547-54. PubMed ID: 17655683 [TBL] [Abstract][Full Text] [Related]
52. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. Blonde L Curr Med Res Opin; 2006 Nov; 22(11):2111-20. PubMed ID: 17076971 [TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. Paick JS; Choi HK; Kim SC; Ahn TY; Kim JJ; Park JK; Park KS; Lee SW; Kim SW; Park K; Jung H; Park NC Asian J Androl; 2008 Sep; 10(5):791-8. PubMed ID: 18645683 [TBL] [Abstract][Full Text] [Related]
54. Sublingual apomorphine for the treatment of erectile dysfunction. Mulhall JP Expert Opin Investig Drugs; 2002 Feb; 11(2):295-302. PubMed ID: 11829718 [TBL] [Abstract][Full Text] [Related]
55. Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. Perimenis P; Markou S; Gyftopoulos K; Giannitsas K; Athanasopoulos A; Liatsikos E; Barbalias G Andrologia; 2004 Jun; 36(3):106-10. PubMed ID: 15206909 [TBL] [Abstract][Full Text] [Related]
56. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. Giammusso B; Colpi GM; Cormio L; Ludovico G; Soli M; Ponchietti R; Montorsi F; Panzironi C; Guastella B Urol Int; 2008; 81(4):409-15. PubMed ID: 19077401 [TBL] [Abstract][Full Text] [Related]
57. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Montorsi F; Verheyden B; Meuleman E; Jünemann KP; Moncada I; Valiquette L; Casabé A; Pacheco C; Denne J; Knight J; Segal S; Watkins VS Eur Urol; 2004 Mar; 45(3):339-44; discussion 344-5. PubMed ID: 15036680 [TBL] [Abstract][Full Text] [Related]
58. Apomorphine-induced brain modulation during sexual stimulation: a new look at central phenomena related to erectile dysfunction. Montorsi F; Perani D; Anchisi D; Salonia A; Scifo P; Rigiroli P; Zanoni M; Heaton JP; Rigatti P; Fazio F Int J Impot Res; 2003 Jun; 15(3):203-9. PubMed ID: 12904807 [TBL] [Abstract][Full Text] [Related]
59. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. Pavone C; Curto F; Anello G; Serretta V; Almasio PL; Pavone-Macaluso M J Urol; 2008 May; 179(5 Suppl):S92-4. PubMed ID: 18405767 [TBL] [Abstract][Full Text] [Related]
60. A prospective evaluation of efficacy and compliance with a multistep treatment approach for erectile dysfunction in patients after non-nerve sparing radical prostatectomy. Gontero P; Fontana F; Zitella A; Montorsi F; Frea B BJU Int; 2005 Feb; 95(3):359-65. PubMed ID: 15679794 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]